They also use the injections to help those following their weight loss programs
Disclosure of interest: Lili Laura Bruta: nothing to disclose Poster session I - DIAGNOSIS / ETIOLOGY 04.00 - DIAGNOSIS / ETIOLOGY - 04.07 - SMALL VESSEL DISEASE P328 - ESOC25-50 CEREBRAL MICROBLEEDS AND THEIR ASSOCIATION WITH INFLAMMATION AND BLOOD BRAIN BARRIER LEAKAGE IN CEREBRAL SMALL VESSEL DISEASE Lupei Cai 1 , Daniel J Tozer 1 , Hugh S Markus 1 1 Stroke Research Group, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom Background and Aims: Cerebral microbleeds (CMBs) are small hypointense lesions visible on paramagnetic-sensitive MR sequences, recognised as a hallmark of small vessel disease (SVD)
Regulatory status: Not approved for human treatment by the FDA Available for research purposes only Not intended for human consumption outside research Researchers are responsible for appropriate use Research ethics: Informed consent is essential for human research Full disclosure of known risks and benefits Appropriate institutional review board (IRB) approval Adherence to good clinical practice (GCP) standards Proper documentation and safety monitoring Athletic use factors: Both peptides are prohibited by WADA Banned in most competitive sports Athletes subject to testing should not use them Researchers working with athletes must ensure compliance Risk Mitigation Strategies To maximize safety during research: Protocol design: Start with standard doses Use the shortest duration necessary Include appropriate safety monitoring Set clear stopping criteria Plan for adverse event management Subject selection: Careful screening to exclude high-risk individuals Thorough medical history and examination Assessment of contraindications Exclusion of those with absolute contraindications Enhanced monitoring for relative contraindications Monitoring and follow-up: Regular safety assessments during research Prompt attention to adverse effects Documentation of all safety findings Follow-up after completion Long-term monitoring if indicated Quality assurance: Use pharmaceutical-grade peptides from reputable sources Verify peptide identity and purity Proper storage and handling Accurate dosing and administration Sterile technique for all injections Emergency Preparedness Protocols should include plans for possible emergencies
When initiated within 48-72 hours of injury, patients typically experience: Reduced intramuscular hematoma formation Faster return of range of motion Lower risk of re-injury upon return to sport Post-Surgical Recovery For patients undergoing orthopedic proceduresrotator cuff repair, ACL reconstruction, Achilles tendon repair, joint arthroplastyBPC-157 can be integrated into the post-operative protocol to: Enhance tendon-to-bone healing at surgical anchors Reduce post-operative pain and swelling Minimize scar tissue formation that limits long-term range of motion Arthritis and Joint Pain While BPC-157 does not regenerate cartilage that has been completely lost, it provides significant benefit for osteoarthritis and inflammatory arthritis by: Reducing synovial inflammation Modulating pain signaling in the joint capsule Supporting the health of remaining cartilage and subchondral bone The PRP and Stem Cell Synergy One of the most powerful applications of BPC-157 is as an adjunct to Platelet Rich Plasma (PRP) and stem cell therapies
